Type 2 Diabetes Clinical Trial
Official title:
The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Walnuts include many potentially beneficial micronutrients and phytochemicals, in this study
we propose to examine the effects of walnuts independent of macronutrient content. The
purpose of this proposal is to study in depth the short-term effects of walnut consumption in
men and women with the metabolic syndrome.
Study Aim 1: To investigate the effects of walnuts (48gms per day over 3 days) on insulin
resistance in subjects with the metabolic syndrome.
Study Aim 2: To investigate the effects of 48gms per day of walnuts over 3 days on lipids and
inflammatory markers.
Study Aim 3: To assess the possible mechanisms of the biological effects of short-term walnut
consumption through assessment of adipokines, resting metabolic rate, gene expression in
white blood cells and the effect of walnuts when consumed as part of a mixed meal, on glucose
excursions, insulin secretion and the excretion of gut peptides and free fatty acids.
During the whole study period, you will be asked to maintain a constant body weight and you
will receive advice from the dietitian regarding a weight stable diet and exercise pattern.
You will also be asked to avoid walnuts during the entire study period. The intervention and
the measurements during each of the visits are described below.
If you agree to be in this study, you will be asked to read and sign this consent form. After
you sign the consent form, the following things will happen:
1. Screening Procedures: Screening procedures are tests and procedures that will be done to
determine if you are eligible to take part in the research study. For this research
study, the screening procedures include:
1. A detailed medical history and interview about lifestyle factors and medication use
2. A brief physical examination to document any abnormalities in your body appearance
and measurement of weight, height and waist circumference.
3. Drawing of blood from the forearm for fasting blood glucose (blood sugar), lipid
profile (cholesterol and other fats in blood), creatinine (a measure of your kidney
function), and complete blood count (CBC).
4. Collection of urine for a HCG pregnancy test (women only)
For the blood tests, you will be asked not to eat or drink anything (except water) from
8 pm the previous evening until you arrive for the study visit the following morning.
Samples of your blood will be stored under code to be used for future research by the
BIDMC investigators but your name will not be identified. If for any reason you have
decided to withdraw from the study or if you have not met the criteria for enrollment
into the study, all the blood drawn at the screening visit will be discarded.
Next, you will meet with a research dietician to receive instructions for the 2-week
run-in period (see below).
2. Randomization Procedures:
You will be randomly assigned (like the flip of a coin) to receive either walnut
containing milkshake or placebo containing milkshake on your first visit. Each
participant will receive walnut containing milkshake during one visit and a milkshake
that looks and tastes the same but without walnuts (placebo) on the other visit but the
order of the visits will be randomized.
3. Research Procedures: If you qualify to take part in this research study, you will
undergo these research procedures:
Run-in period:
You will meet with a research dietician who will provide instructions about maintaining
your normal diet and physical activity pattern and about avoiding walnut-containing
foods and drinks.
Study Visit 1 and 2 Each study visit involves a 4-day (4 overnight) stay at the General
Clinical Research Center. You will be admitted at 9pm the evening before the first day
of the visit. You will be asked to complete a hunger questionnaire each morning before
you have had anything to eat. You will receive a milkshake each morning containing
either with or without walnuts. We will repeat the hunger questionnaire before your
lunch each day. You will be provided with lunch and dinner based on what you like to
eat. The calorie content of the lunch and dinner will be controlled so that you will
neither gain or lose weight during your stay.
Day 1 The following morning the following tests will be performed; Measure your weight,
waist circumference, and blood pressure. Resting Metabolic Rate Fasting blood tests Body
composition Mixed meal challenge You will receive your first milkshake as part of the
mixed meal challenge.
Day 2 On day 2 there is no testing but you will complete the hunger questionnaire and
receive another milkshake for breakfast.
Day 3
On day 3 you will have the following tests performed:
Insulin Suppression Test Fasting blood sample At the end of the insulin suppression
test, you will receive another milkshake.
Day 4 On the morning of your last day you will have repeat testing as on the first day
of the visit and will leave the hospital at mid-day after the testing is complete.
Washout phase Between the 2 study visits you will enter a washout phase where you will
continue your normal healthy diet and exercise but avoid walnuts in your diet. After 1
month of washout you will return to the GCRC for your second study visit.
4. Tests performed during the study
Resting Metabolic Rate RMR is the amount of calories you burn without doing any physical
work. Your RMR will be measured with a commonly used instrument. You will be asked to lie
quietly in bed and stay awake with a large plastic hood over your head and upper body for
about 20 minutes and breathe normally while the air you breathe out is being collected.
Fasting blood tests Blood samples will be used to measure sugar, insulin levels, lipids (LDL,
HDL, and total cholesterol, triglycerides), hormones (such as leptin, resistin and
adiponectin) and blood markers of inflammation (such as TNF and CRP). We will also perform a
blood test to measure the expression of genes involved in metabolism in your white blood
cells. For the blood tests, you will be asked not to eat or drink anything (except water)
from 8 pm the previous evening until. In addition, you will be asked not to participate in
vigorous physical activity on the day before the visit. Samples of your blood will be stored
under code to be used for future related blood measurements by the BIDMC investigators but
your name will not be identified.
Body composition To measure the amount of fat in your body we will use bioelectrical
impedance analysis. During this procedure you will lie down and the speed of an electric
signal through your body will be measured. This signal is not painful.
Mixed meal challenge You will have a small catheter (a small plastic tube) placed in a vein
with a needle in your forearm to draw blood. This will prevent the need for multiple needle
sticks for the required blood draws. The catheter will be taped to stay in place for
approximately three hours. You will drink a milkshake and your blood will be drawn through
the catheter 15 min after the milkshake is given and then at 30-minute intervals for 3 hours
to measure how you metabolize the nutrient drink.
Insulin Suppression Test (also called Galvin's Index) This test consists of an overnight fast
(nothing to eat or drink after 11pm the night before), after which two IV lines will be
placed in your arms. Glucose, insulin,octreotide (a hormone commonly used in clinical
practice for treating several different diseases) and albumin ( a protein found in blood)
will be infused through the IV. Blood samples will be drawn through the other IV line at
times -10 minutes, 0 minutes, and every 30 minutes for two and a half hours, then every 10
minutes for an additional 30 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |